DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Innovations in Treating COPD Exacerbations: Pilot Project on Action Plans Using New Technology.

Information source: McGill University Health Center
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: COPD

Intervention: COPD self-management using an action plan (Behavioral); Telesystem-Phone self-assessment/reporting system (Device); Nurse case manager support (Other)

Phase: N/A

Status: Recruiting

Sponsored by: McGill University Health Center

Official(s) and/or principal investigator(s):
Jean Bourbeau, MD, FRCPC, Principal Investigator, Affiliation: McGill University Health Center

Overall contact:
Jean Bourbeau, MD,FRCPC, Phone: 514-934-1934, Ext: 32185, Email: jean.bourbeau@mcgill.ca

Summary

The purpose of this project is to conduct a pilot study evaluating the feasibility and potential benefits of a phone assessment/reporting system (tele-system) in addition to a written action plan and nurse case manager support to improve patients' adherence to COPD treatment in those at risk for exacerbations. Primary objective: explore the potential benefits with respect to patient's adherence, i. e., prompt use of the antibiotic and/or prednisone in the event of an exacerbation, increased adherence to maintenance medication; to increase patient's self-efficacy" in self-managing their disease; and to use more efficiently program resources, i. e., the case-manager. Secondary objectives: To assess the proportion of patients who effectively self manage exacerbations by using their COPD Action Plan To assess self management of COPD patients with respect to the increased adherence to regular respiratory medication, (SmartInhaler electronic monitoring); To assess increased self-efficacy in COPD patients identifying and managing exacerbations (baseline vs after 12 months); To assess symptoms recovery, health status improvement, and prevention of ER visits and hospital admissions for COPD exacerbations. To assess the efficiency in using program resources, To evaluate the feasibility of this treatment approach and to provide pilot data (needed for a larger multi-centre clinical trial; To evaluate the feasibility and need of assessment during and after exacerbation onset, health-related quality of life and physical activity; To evaluate the safety of this approach; this is in terms of the delay in starting prednisone and an unfavourable outcome (ER visits and/or hospitalization).

Clinical Details

Official title: Pilot Study Evaluating the Feasibility and Potential Benefits of a Novel Approach of COPD Self-management That Includes a Phone Assessment/Reporting System (Tele-system)

Study design: Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care

Primary outcome: - Patient adherence to action plan

Secondary outcome:

Respiratory medication adherence

Self-efficacy to manage exacerbations:

Health care utilization

Phone System

Detailed description: BACKGROUND: Chronic Obstructive Pulmonary Disease (COPD) is the 4th leading cause of death in Canada and the only chronic disease where mortality rates continue to climb. Acute exacerbations are common. Unfortunately, exacerbations are often viewed as trivial events or "simple bronchitis"despite being linked with accelerated lung function decline, poor health, hospital admissions and premature death. Conversely, prompt treatment reduces recovery time,improves health status, and decrease hospital admissions. In most patients, exacerbations are managed either in primary care walk-in clinics or emergency departments (ED), resulting in suboptimal management and high utilization costs. Furthermore, less severe exacerbations (~60%) remain unreported and untreated, although these likely have a significant negative impact on health. In Canada, quality indicators suggest that chronic disease management remains suboptimal, especially in COPD. RATIONALE: In COPD clinics, the investigators group and others have shown that patients who learn how to self-monitor and manage acute exacerbations by following a COPD Action Plan have better health outcomes and lower rates of health care utilization (unplanned office visits, ED use, and hospital admissions). Key elements of effective self-management programs include a written Action Plan, standing orders for exacerbation medications (antibiotics/prednisone), and self-management skills training combined with access to nurse case manager support. However, these programs are time and resource intensive and hence very challenging to implement across practices, especially in those that are not specialized. Recent advances in patient-provider communication technology, such as interactive phone systems, show promise in helping inform and motivate patients with asthma, diabetes and hypertension to effectively self monitor symptoms and better self-manage their diseases. Communication technology offers new opportunities to develop chronic disease self-management programs that can be easily implemented and less likely to place additional burden on busy practices.

Eligibility

Minimum age: 40 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Patients will be adults with COPD at high risk for exacerbations

- Post bronchodilator spirometry FEV1 <80% pred. and FEV1/FVC <0. 70

- Aged ≥ 40 yrs

- Smoking ≥ 10 pack-years

- 1 or more exacerbations requiring antibiotic or prednisone in the last year. (This is

the population with the highest chance of having another exacerbation

- Combination therapy LABA-ICS (Advair) with or without an anticholinergic (Spiriva or

Atrovent) and a rescue SABA (Ventolin) Exclusion Criteria:

- Combination therapy LABA-ICS other than Advair

- Home oxygen for 18-24 hours/day

- Chronic CO2 retention

- Previous NIMV/MV

- Cognitive impairment

- Does not speak English or French fluently

- Severe co-morbidities such as bronchiectasis with recurrent infections, severe left

congestive heart failure

- Survival <6 months

- Any significant medical condition other than COPD that may also result in dyspnea

(e. g. unstable angina, BMI > 40).

Locations and Contacts

Jean Bourbeau, MD,FRCPC, Phone: 514-934-1934, Ext: 32185, Email: jean.bourbeau@mcgill.ca

Montreal Chest Institute, Montreal, Quebec H2X2P4, Canada; Recruiting
Jean Bourbeau, MD, FRCPC, Principal Investigator
Additional Information

Starting date: October 2013
Last updated: April 7, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017